Cardiac Gene Therapy

Merging Companies to Develop Heart Disease and Cell Transplantation Therapies

Published in Gene Therapy Weekly, November 23rd, 2000

Cardiogene AG, Erkrath, Germany, and Intracardia, Inc., Cincinnati, Ohio, announced that they have merged to create a transatlantic biopharmaceutical company pursuing multiple product opportunities in heart disease and cell transplantation.

In conjunction with the merger, Cardiogene is changing its name to Cardion AG to reflect the broadening of its product portfolio and repository of technology platforms. The combined entity will retain corporate headquarters in Erkrath, Germany, and establish U.S. operations in Boston, Massachusetts.

Cardion combines Cardiogene's core local gene therapy platform with Intracardia's strengths in stem cell...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2000-11-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry